Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMURH4X)

• Drug Name: Oxypurinol Drug Info
• Synonyms: Oxypurinol (intravenous)

Indication

Disease Entry	ICD 11	Status	REF
Heart failure	BD10-BD13	Phase 2/3	[1]

• Cross-matching ID:
  PubChem CID: 135398752
  ChEBI ID: CHEBI:28315
  CAS Number: CAS 2465-59-0
  TTD Drug ID: DMURH4X
  VARIDT Drug ID: DR00123

Molecule-Related Drug Atlas

Drug(s) Transported By Urate anion exchanger 1 (SLC22A12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Uric acid	DMA1MKT	Discovery agent	N.A.	Investigative	[4]
Orotate	DMMB29S	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopurinol	DMLPAOB	Hyperuricaemia	5C55.Y	Approved	[6]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[7]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[8]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[10]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[11]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[12]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[13]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[14]
Fused heterocyclic compound 3	DM2QVHY	N. A.	N. A.	Patented	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Xanthine dehydrogenase/oxidase (XDH)	TT7RJY8	XDH_HUMAN	Inhibitor	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Urate anion exchanger 1 (SLC22A12)	DT2WLAD	S22AC_HUMAN	Substrate	[3]

References

• [1] ClinicalTrials.gov (NCT00063687) Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure. U.S. National Institutes of Health.
• [2] Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
• [3] Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos. 2005 Dec;33(12):1791-5.
• [4] Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007 Jan;320(1):211-7.
• [5] Human urate transporter 1 (hURAT1) mediates the transport of orotate. J Physiol Sci. 2011 May;61(3):253-7.
• [6] Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
• [7] Clinical pipeline report, company report or official report of Takeda (2009).
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [9] Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
• [10] Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
• [11] QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
• [12] Clinical pipeline report, company report or official report of Teijin Pharma.
• [13] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
• [14] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.